OneMedNet partners with Medcase to enhance healthcare data annotation services, expanding their market presence in AI-driven healthcare solutions.
Quiver AI Summary
OneMedNet Corporation has announced a strategic partnership with Medcase, a leader in medical data annotation, to enhance its position in the fast-growing healthcare data annotation market, projected to grow from $1.5 billion in 2025 to $2.8 billion by 2030. This collaboration will allow OneMedNet to access Medcase's network of over 15,000 healthcare professionals for high-quality data annotation while utilizing its proprietary iRWD™ platform to provide regulatory-grade, de-identified real-world data. The partnership aims to meet the rising demand for specialized healthcare data, positioning both companies to deliver recurring revenue streams in the healthcare AI sector. As healthcare data becomes increasingly critical for AI development, this alliance consolidates OneMedNet's role in the healthcare data ecosystem, supporting long-term growth objectives in a market with significant potential.
Potential Positives
- OneMedNet has formed a strategic partnership with Medcase, positioning itself to enter a high-growth revenue channel within the $1.5 billion healthcare data annotation market.
- The collaboration enables OneMedNet to leverage Medcase's network of over 15,000 healthcare professionals, enhancing its capacity to provide regulatory-compliant, high-quality Real-World Data.
- This partnership is expected to create new growth opportunities by combining OneMedNet's iRWD™ platform with specialized annotation services, which addresses a significant market need.
- Healthcare is identified as the fastest-growing vertical in the data annotation industry, providing a defensible market position for OneMedNet and paving the way for recurring, high-margin revenue streams.
Potential Negatives
- Partnership details could raise concerns about dependency on Medcase for expertise in healthcare data annotation.
- The mention of significant competition in the market may indicate that OneMedNet faces uphill challenges in establishing its position.
- The press release contains cautionary statements regarding forward-looking projections, highlighting potential risks in achieving future performance goals.
FAQ
What is the new partnership announced by OneMedNet?
OneMedNet has formed a strategic partnership with Medcase to enhance healthcare data annotation and expand into new markets.
How will the partnership benefit OneMedNet?
The collaboration allows OneMedNet to access a high-growth revenue channel and improve its offerings in the healthcare AI ecosystem.
What is the healthcare data annotation market's projected growth?
The healthcare data annotation market is projected to grow from $1.5 billion in 2025 to $2.8 billion by 2030.
How does OneMedNet's iRWD™ platform enhance this partnership?
Medcase will leverage OneMedNet’s iRWD™ platform for access to regulatory-grade Real-World Data, improving annotation quality and competitiveness.
What unique advantages does this partnership offer?
The partnership combines expert annotation services with high-quality data, providing a unique competitive edge in the healthcare AI sector.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ONMD Hedge Fund Activity
We have seen 5 institutional investors add shares of $ONMD stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HRT FINANCIAL LP added 182,638 shares (+inf%) to their portfolio in Q2 2025, for an estimated $104,121
- CKW FINANCIAL GROUP removed 100,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $57,010
- EXENCIAL WEALTH ADVISORS, LLC added 45,448 shares (+3.1%) to their portfolio in Q2 2025, for an estimated $25,909
- XTX TOPCO LTD added 35,900 shares (+inf%) to their portfolio in Q2 2025, for an estimated $20,466
- CITADEL ADVISORS LLC removed 28,058 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $15,995
- GEODE CAPITAL MANAGEMENT, LLC removed 15,869 shares (-10.4%) from their portfolio in Q2 2025, for an estimated $9,046
- VIRTU FINANCIAL LLC removed 14,515 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $8,275
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MINNEAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announced a strategic partnership with Medcase, a worldwide network of healthcare professionals focused on medical data annotation. This collaboration establishes a new market entry point for OneMedNet and opens a high-growth revenue channel in the healthcare AI ecosystem.
Strategic Expansion into Healthcare Data Annotation
The global healthcare data annotation market, valued at $1.5 billion in 2025 and projected to be $2.8 billion by 2030, has entered a pivotal growth phase 1 . Scale AI’s $14.8B investment from Meta has disrupted the industry, triggering an exodus of major clients concerned about competitive intelligence. This shift has created an immediate opportunity for specialized providers focused solely on healthcare—where regulatory compliance, domain expertise, and trust are paramount. With Medcase’s 15,000+ healthcare professionals delivering world-class annotation services, OneMedNet gains a strategic foothold in this fast-growing market, expanding beyond RWD into a complementary and recurring revenue stream.
Leveraging OneMedNet’s Proprietary iRWD™ Platform
In turn, Medcase will leverage OneMedNet’s nationwide provider network and iRWD™ platform to give its clients access to regulatory-grade, de-identified Real-World Data across clinical data including imaging, and EHR data. This combination of high-quality RWD with expert annotation represents a unique competitive advantage for both companies—one that cannot be easily replicated by generalist data players.
High-Growth Market Opportunity
- 58% YoY headcount growth among healthcare-specific data curation providers underscores the market’s acceleration 2 .
- Domain-specific, proprietary data is increasingly the critical differentiator in AI model development.
-
Healthcare remains the largest and most regulated opportunity in AI training data, with rising demand for privacy-compliant, longitudinal datasets
2
.
“This partnership positions OneMedNet at the center of the healthcare data value chain,” said Aaron Green, CEO & President of OneMedNet. “By combining our iRWD™ platform with Medcase’s annotation expertise, we are extremely well positioned to serve a large unmet market need, unlocking new growth channels that directly strengthen our long-term revenue trajectory.”
“The demand for specialized healthcare annotation is accelerating faster than ever,” said Niv Shochat, CEO of Medcase. “By aligning with OneMedNet, we can now offer our clients access to unparalleled Real-World Data, creating a defensible position in one of AI’s most valuable verticals.”
Positioned for Scale
The global data annotation industry spans multiple enterprise sectors—including automotive, retail, and fintech—but healthcare stands apart as the fastest-growing and most defensible vertical. Together, OneMedNet and Medcase are positioned to deliver recurring, high-margin revenue streams by meeting the unique requirements of healthcare AI developers, pharmaceutical companies, and medical technology leaders.
-
Healthcare Data Collection & Labeling Market Size 2025-2030. (n.d.). -
https://www.360iresearch.com/library/intelligence/healthcare-data-collection-labeling
-
CB Insights -
https://www.cbinsights.com/esp/enterprise-tech/bi-&-operational-intelligence/data-annotation
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,750 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com .
About MedCase
Medcase Health is a global leader in clinician-led medical data enrichment and healthcare AI services. We connect AI developers, pharmaceutical companies, and medtech leaders with verified health care professionals who deliver precise, specialty-specific labeling across imaging, medical device data, electronic health records and more. Beyond annotation, we provide expert-led audits, FDA-compliant reader studies, and quality oversight to ensure regulatory-grade datasets.
Through collaborations with some of the world’s most prominent technology companies and fast-growing health AI startups, we combine clinical expertise with advanced data enrichment platforms to accelerate model training, improve accuracy, and reduce time to market. With more than 15,000 clinicians worldwide, Medcase enables organizations to scale quickly, meet complex regulatory requirements, and power the next generation of healthcare innovation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. We base these forward-looking statements on our current expectations and projections about future events, which we derive from the information presently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations..
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
SOURCE: ONEMEDNET CORPORATION